Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Sep 24;56(3):2001919.
doi: 10.1183/13993003.01919-2020. Print 2020 Sep.

JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk

Puja Mehta  1   2 , Coziana Ciurtin  2 , Marie Scully  3 , Marcel Levi  4 , Rachel C Chambers  5
Affiliations
Comment

JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk

Puja Mehta et al. Eur Respir J. .

Abstract

JAK inhibitors have promising therapeutic potential in COVID-19 with dual anti-inflammatory and anti-viral effects. Vigilance to the potentially increased thrombotic risk associated with JAKi is recommended, given the hypercoagulability of COVID-19. https://bit.ly/2NQ15K5

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: P. Mehta is an MRC-GSK EMINENT clinical training fellow with project funding outside the submitted work, and receives co-funding by the NIHR University College London Hospitals Biomedical Research Centre (UCLH BRC). Conflict of interest: C. Ciurtin has nothing to disclose. Conflict of interest: M. Scully has nothing to disclose. Conflict of interest: M. Levi has nothing to disclose. Conflict of interest: R.C. Chambers reports grants from UKRI MRC, GlaxoSmithKline and NIHR ULCH BRC, unrelated to this work.

Comment on

  • Pulmonary embolism in patients with COVID-19 pneumonia.
    Bompard F, Monnier H, Saab I, Tordjman M, Abdoul H, Fournier L, Sanchez O, Lorut C, Chassagnon G, Revel MP. Bompard F, et al. Eur Respir J. 2020 Jul 30;56(1):2001365. doi: 10.1183/13993003.01365-2020. Print 2020 Jul. Eur Respir J. 2020. PMID: 32398297 Free PMC article.

References

    1. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 135: 2033–2040. - PMC - PubMed
    1. Bompard F, Monnier H, Saab I, et al. . Pulmonary embolism in patients with COVID-19 pneumonia. Eur Respir J 2020; 56: 2001365. doi:10.1183/13993003.01365-2020 - DOI - PMC - PubMed
    1. Criel M, Falter M, Jaeken J, et al. . Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it? Eur Respir J 2020; 56: 2001201. - PMC - PubMed
    1. Mehta P, McAuley DF, Brown M, et al. . COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033–1034. - PMC - PubMed
    1. Stebbing J, Phelan A, Griffin I, et al. . COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020; 20: 400–402. doi:10.1016/S1473-3099(20)30132-8 - DOI - PMC - PubMed

Substances